Travis H. Stracker, Ph.D.

Travis H. Stracker, Ph.D.

Travis Stracker’s research focuses on understanding how cells respond to DNA damage and maintain genomic stability. Defects in the cellular response to DNA damage underlie rare diseases associated with cancer predisposition and are exploitable vulnerabilities for cancer therapy. The lab uses a variety of approaches to further understand the signal transduction pathways triggered by radio and chemotherapy and to identify new therapeutic targets.

Areas of Expertise

1) DNA damage response, 2) chromosomal instability, 3) DNA repair, 4) chromatin assembly, 5) microcephaly, 6) synthetic lethality

Contact Info

Travis H. Stracker, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room B3B406
Bethesda, MD 20892
Ph: 240-383-6006

Dr. Stracker’s research focuses on understanding how cancer cells respond to radiotherapy, and other DNA damaging chemotherapies, and how these responses can be modulated for therapeutic gain.

A major line of research in the lab focuses on understanding the molecular functions of the Tousled-like kinases (TLKs), TLK1 and TLK2. The TLKs play a key role in chromatin assembly through the regulation of the ASF1 histone chaperones and mutations in TLK2 have been implicated in a distinct neurodevelopmental disorder characterized by microcephaly and intellectual disability. TLK activity is regulated by the DNA damage response and their depletion provokes innate immune signaling and enhances cellular sensitivity to DNA damaging agents. The Stracker lab is investigating the role of the TLKs in neurodevelopmental disorders and exploring their potential as a target for cancer therapy.

A second line of research is aimed at identifying synthetic lethal genetic interactions that can exploited for cancer therapy. The laboratory uses CRISPR/Cas9-based screening approaches to identify genes that modulate cellular sensitivity to radiotherapy and chemotherapy. The molecular mechanisms of these genetic interactions will be defined and promising leads will be explored in pre-clinical models of cancer.

NIH Scientific Focus Areas:
Cancer Biology, Cell Biology, Chromosome Biology, Genetics and Genomics, Molecular Biology and Biochemistry
  1. Segura-Bayona S, Stracker TH.
    Cell Mol Life Sci. 76(19): 3827-3841, 2019. [ Journal Article ]
  2. Lee SB, Segura-Bayona S, Villamor-Payà M, Saredi G, Todd MAM, Attolini CS, Chang TY, Stracker TH, Groth A.
    Sci Adv. 4(8): eaat4985, 2018. [ Journal Article ]
  3. Mortuza GB, Hermida D, Pedersen AK, Segura-Bayona S, López-Méndez B, Redondo P, Rüther P, Pozdnyakova I, Garrote AM, Muñoz IG, Villamor-Payà M, Jauset C, Olsen JV, Stracker TH, Montoya G.
    Nat Commun. 9(1): 2535, 2018. [ Journal Article ]
  4. Silva J, Aivio S, Knobel PA, Bailey LJ, Casali A, Vinaixa M, Garcia-Cao I, Coyaud É, Jourdain AA, Pérez-Ferreros P, Rojas AM, Antolin-Fontes A, Samino-Gené S, Raught B, González-Reyes A, Ribas de Pouplana L, Doherty AJ, Yanes O, Stracker TH.
    Nat Cell Biol. 20(2): 162-174, 2018. [ Journal Article ]
  5. Segura-Bayona S, Knobel PA, González-Burón H, Youssef SA, Peña-Blanco A, Coyaud É, López-Rovira T, Rein K, Palenzuela L, Colombelli J, Forrow S, Raught B, Groth A, de Bruin A, Stracker TH.
    Cell Death Differ. 24(11): 1872-1885, 2017. [ Journal Article ]

Dr. Stracker received his undergraduate degree in Genetics from the University of Georgia in 1996. He performed his graduate training in the University of California, San Diego Biology program, where he worked in the laboratory of Dr. Matthew Weitzman at the Salk Insitute for Biological Studies. His thesis work uncovered mechanisms used by DNA viruses to disable key components of the DNA damage response. In 2003, he joined the laboratory of Dr. John Petrini in the Molecular Biology Program of Sloan-Kettering Institute. There his research focused on the generation and characterization of mouse models of cancer susceptibility and rare diseases associated with genomic instability. Dr. Stracker started his own laboratory in the IRB Barcelona Cancer Science Program in 2009, where he continued to study the DNA damage response and its implications in rare diseases, cancer and cancer therapy. Finally, in July of 2020, he joined the NCI as an Investigator in the Radiation Oncology Branch.